{"entity":{"id":"bridgebio-oncology-therapeutics","kind":"company","name":"BridgeBio Oncology Therapeutics","aka":["QED Therapeutics, a BridgeBio company","QED Therapeutics"],"tldr":"BridgeBio Oncology Therapeutics (BBOT) makes pills against the KRAS cancer protein and a drug that stops KRAS from switching on a second growth signal called PI3K-alpha. All three drugs are in early human trials.","summary":"BridgeBio Oncology Therapeutics (BBOT) is a South San Francisco clinical-stage company spun out of BridgeBio and focused on RAS pathway cancers. Its three clinical programmes are BBO-8520, a KRAS G12C inhibitor binding both ON and OFF states, in the phase 1 ONKORAS-101 trial in KRAS G12C non-small cell lung cancer; BBO-11818, a pan-KRAS inhibitor in the phase 1 KONQUER-101 trial in KRAS-mutant solid tumours; and BBO-10203, a RAS-PI3K-alpha interaction inhibitor ('breaker') in the phase 1 BREAKER-101 trial in HER2-positive and HR-positive/HER2-negative breast cancer and KRAS-mutant colorectal and lung cancer. BBOT listed on Nasdaq on 11 August 2025 through a business combination with Helix Acquisition Corp. II, a SPAC sponsored by affiliates of Cormorant Asset Management, with a 261 million US dollar PIPE and about 382 million US dollars in gross proceeds; it expected roughly 490 million US dollars in cash at closing.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://bbotx.com/"},{"label":"Pipeline","url":"https://bbotx.com/pipeline/"},{"label":"Listing press release, August 2025 (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/ea025066201ex99-4_bridge.htm"}],"tags":[],"related":[],"cancers":["nsclc","colorectal","breast-her2-positive","breast-hr-positive"],"sections":["targeted-therapy"],"technologies":["kras-inhibitors"],"targets":["kras","pik3ca"],"drugs":["infigratinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The hint said Palo Alto; the listing press release datelines South San Francisco and Boston. Founding year not sourced."],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://bbotx.com/","ticker":"BBOT","stage":"public","investors":["cormorant-asset-management"],"funding":[{"round":"IPO","year":2025,"amountUsd":382000000,"source":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/ea025066201ex99-4_bridge.htm","note":"Nasdaq listing via merger with Helix Acquisition Corp. II on 11 August 2025; about 261 million US dollar PIPE led by Cormorant plus about 120 million from the trust, roughly 382 million gross"}]},"route":"/companies/bridgebio-oncology-therapeutics/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/"}],"drug":[{"id":"infigratinib","kind":"drug","name":"Infigratinib","route":"/drugs/infigratinib/"}],"company":[{"id":"cormorant-asset-management","kind":"company","name":"Cormorant Asset Management","route":"/companies/cormorant-asset-management/"}]}}